Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...
AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its ...
Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...
AbbVie (ABBV) dropped 4.69% after FDA approved J&J's Icotyde psoriasis pill, creating fresh competition for blockbuster drug ...
By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Shares of AbbVie ABBV fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as ...
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
Everyday Health on MSN
FDA approves first-of-its-kind daily pill for moderate to severe psoriasis
The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results